Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Amyotrophic lateral sclerosis (ALS) is a rapidly progressive, devastating and fatal disease characterized by selective loss of upper and lower motor neurons of the cerebral cortex, brainstem, spinal cord and muscle atrophy. In spite of many years of research, the pathogenesis of ALS is still not well understood. ALS is a multifaceted genetic disease, in which genetic susceptibility to motor neuron death interacts with environmental factors and there is still no cure for this deleterious disease. At present, there is only one FDA approved drug, Riluzole which according to past studies only modestly slows the progression of the disease, and improves survival by up to three months. The suffering of the ALS patients, and their families is enormous and the economic burden is colossal. There is therefore a pressing need for new therapies. Different molecular pathways and pathological mechanisms have been implicated in ALS. According to past studies, altered calcium homeostasis, abnormal mitochondrial function, protein misfolding, axonal transport defects, excessive production of extracellular superoxide radicals, glutamate-mediated excitotoxicity, inflammatory events, and activation of oxidative stress pathways within the mitochondria and endoplasmic reticulum can act as major contributor that eventually leads to loss of connection between muscle and nerve ultimately resulting to ALS. However, the detailed molecular and cellular pathophysiological mechanisms and origin and temporal progression of the disease still remained elusive. Ongoing research and future advances will likely advance our improve understanding about various involved pathological mechanism ultimately leading to discoveries of new therapeutic cures. Importantly, clinical biomarkers of disease onset and progression are thus also urgently needed to support the development of the new therapeutic agents and novel preventive and curative strategies. Effective translation from pre-clinical to clinical studies will further require extensive knowledge regarding drug activity, bioavailability and efficacy in both the pre-clinical and clinical setting, and proof of biological activity in the target tissue. During the last decades, the development of new therapeutic molecules, advance neuroimaging tools, patient derived induced stem cells and new precision medicine approaches to study ALS has significantly improved our understanding of disease. In particular, new genetic tools, neuroimaging methods, cellular probes, biomarker study and molecular techniques that achieve high spatiotemporal resolution have revealed new details about the disease onset and its progression. In our effort to provide the interested reader, clinician and researchers a comprehensive summaries and new findings in this field of ALS research, hereby we have created this electronic book which comprises of twenty seven chapters having various reviews, perspective and original research articles. All these chapters and articles in this book not only summarize the cutting-edge techniques, approaches, cell and animal models to study ALS but also provide unprecedented coverage of the current developments and new hypothesis emerging in ALS research. Some examples are novel genetic and cell culture based models, mitochondria-mediated therapy, oxidative stress and ROS mechanism, development of stem cells and mechanism-based therapies as well as novel biomarkers for designing and testing effective therapeutic strategies that can benefit ALS patients who are at the earlier stages in the disease. I am extremely grateful to all the contributors to this book and want to thank them for their phenomenal efforts. Amyotrophic lateral sclerosis (ALS) is a rapidly progressive, devastating and fatal disease characterized by selective loss of upper and lower motor neurons of the cerebral cortex, brainstem, spinal cord and muscle atrophy. In spite of many years of research, the pathogenesis of ALS is still not well understood. ALS is a multifaceted genetic disease, in which genetic susceptibility to motor neuron death interacts with environmental factors and there is still no cure for this deleterious disease. At present, there is only one FDA approved drug, Riluzole which according to past studies only modestly slows the progression of the disease, and improves survival by up to three months. The suffering of the ALS patients, and their families is enormous and the economic burden is colossal. There is therefore a pressing need for new therapies. Different molecular pathways and pathological mechanisms have been implicated in ALS. According to past studies, altered calcium homeostasis, abnormal mitochondrial function, protein misfolding, axonal transport defects, excessive production of extracellular superoxide radicals, glutamate-mediated excitotoxicity, inflammatory events, and activation of oxidative stress pathways within the mitochondria and endoplasmic reticulum can act as major contributor that eventually leads to loss of connection between muscle and nerve ultimately resulting to ALS. However, the detailed molecular and cellular pathophysiological mechanisms and origin and temporal progression of the disease still remained elusive. Ongoing research and future advances will likely advance our improve understanding about various involved pathological mechanism ultimately leading to discoveries of new therapeutic cures. Importantly, clinical biomarkers of disease onset and progression are thus also urgently needed to support the development of the new therapeutic agents and novel preventive and curative strategies. Effective translation from pre-clinical to clinical studies will further require extensive knowledge regarding drug activity, bioavailability and efficacy in both the pre-clinical and clinical setting, and proof of biological activity in the target tissue. During the last decades, the development of new therapeutic molecules, advance neuroimaging tools, patient derived induced stem cells and new precision medicine approaches to study ALS has significantly improved our understanding of disease. In particular, new genetic tools, neuroimaging methods, cellular probes, biomarker study and molecular techniques that achieve high spatiotemporal resolution have revealed new details about the disease onset and its progression. In our effort to provide the interested reader, clinician and researchers a comprehensive summaries and new findings in this field of ALS research, hereby we have created this electronic book which comprises of twenty seven chapters having various reviews, perspective and original research articles. All these chapters and articles in this book not only summarize the cutting-edge techniques, approaches, cell and animal models to study ALS but also provide unprecedented coverage of the current developments and new hypothesis emerging in ALS research. Some examples are novel genetic and cell culture based models, mitochondria-mediated therapy, oxidative stress and ROS mechanism, development of stem cells and mechanism-based therapies as well as novel biomarkers for designing and testing effective therapeutic strategies that can benefit ALS patients who are at the earlier stages in the disease. I am extremely grateful to all the contributors to this book and want to thank them for their phenomenal efforts.

Mitochondria --- neurodegenerative disease --- Ca2+ signaling --- multidrug therapy --- Amyotrophic lateral sclerosis (ALS) --- Superoxide dismutase 1 (SOD1) --- Motor neuron disease (MND) --- excitotoxicity --- Riluzole --- multifactorial disease

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This Special Issue is a collection of research articles focused on the production and role of nitric oxide in plants. Nitric oxide is a crucial molecule used in the orchestration of cellular events in animals and plants. With a mixture of primary research papers and review articles written by some of the top researchers in the field, this work encompasses many aspects of this important and growing area of biochemistry.

catalase --- monodehydroascorbate reductase --- tyrosine nitration --- nitric oxide --- peroxisome --- reactive oxygen species --- S-nitrosation --- superoxide dismutase --- antioxidants --- hydrogen gas --- hydrogen peroxide --- hydrogen sulfide --- S-nitrosothiols --- S-nitrosoglutathione reductase --- S-(hydroxymethyl)glutathione --- nitrate reductase --- NOFNiR --- nitrogen metabolism --- NIA1 --- NIA2 --- nitrite --- nitrate --- methyl viologen --- benzyl viologen --- NO analyzer --- molybdenum cofactor --- Arabidopsis thaliana --- nitro-fatty acids --- nitroalkenes --- nitroalkylation --- electrophile --- nucleophile --- signaling mechanism --- post-translational modification --- reactive lipid species --- nitro-lipid-protein adducts --- Trebouxia --- microalgae --- lipid peroxidation --- diaphorase activity --- lichens --- nitric oxide synthase --- nitrogen dioxide --- plant growth --- cell enlargement --- cell proliferation --- early flowering --- PsbO --- nitric oxide homeostasis --- cue1/nox1 --- reactive nitrogen species --- germination --- root development --- stress responses --- sugar metabolism --- nitration --- S-nitrosylation --- SNO-reductase --- thiol modification

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This Special Issue is intended as a platform for interactive material science articles with an emphasis on the preparation, functionalization chemistry, and characterization of nanocarbon compounds, as well as all aspects of physical properties of functionalized, conjugated, or hybrid nanocarbon materials, and their associated applications. Some recent advances in the field are here collected, providing new ideas for discussion of researchers working in this multidisciplinary scenario.

graphene oxide --- thermal conductivity --- vacancy defect --- omeprazole --- liquid chromatography --- tandem mass spectrometry --- saliva --- GO-Tabs --- Tri[60]fullerenyl stereoisomers --- cis-cup-form of 3D-stereoisomers --- tris(diphenylaminofluorene) --- 3D-configurated nanostructures --- intramolecular energy transfer for singlet oxygen production --- intramolecular electron transfer for superoxide radical production --- graphene-based materials --- nanoporous graphene --- epitaxial graphene --- molecular modeling --- filled carbon nanotubes --- lithium-ion batteries --- hybrid nanomaterials --- anode material --- carbon nanotube yarns --- carbon nanotube --- functionalization --- electrical conductivity --- annealing --- acid treatment --- carbon fibers --- surface treatment --- grafting --- graphene aerogel --- carbon nanostructures --- carbon nanohybrids --- cancer therapy --- multi-drug resistance

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

[Increasing evidence suggests that microbiota and especially the gut microbiota (the microbes inhabiting the gut including bacteria, archaea, viruses, and fungi) plays a key role in human physiology and pathology. Recent findings indicate how dysbiosis—an imbalance in the composition and organization of microbial populations—could severely impact the development of different medical conditions (from metabolic to mood disorders), providing new insights into the comprehension of diverse diseases, such as IBD, obesity, asthma, autism, stroke, diabetes, and cancer. Given that microbial cells in the gut outnumber host cells, microbiota influences human physiology both functionally and structurally. Microbial metabolites bridge various—even distant—areas of the organism by way of the immune and hormone system. For instance, it is now clear that the mutual interaction between the gastrointestinal tract and the brain (gut–brain axis), often involves gut microbiota, indicating that the crosstalk between the organism and its microbial residents represents a fundamental aspect of both the establishment and maintenance of healthy conditions. Moreover, it is crucial to recognize that beyond the intestinal tract, microbiota populates other host organs and tissues (e.g., skin and oral mucosa). We have edited this eBook with the aim of publishing manuscripts focusing on the impact of microbiota in the development of different diseases and their associated treatments.]

gastrointestinal diseases --- sterile inflammation --- n/a --- Staphylococcus spp. --- etiopathogenesis --- colitis --- Escherichia coli --- bacteriophages --- atopic dermatitis --- intravenous immunoglobulin G --- adaptive immunity --- 16S rRNA gene --- vaginal microbiota --- modularity --- innate immunity --- gut-liver axis --- disease activity --- immune system --- cytokines --- commensals --- Staphylococcus aureus --- dysbiosis --- fecal transplantation --- TLR mimicry --- etanercept --- dextran sulfate sodium --- CAR T-cell --- 3-dihydroxy-4-methoxyBenzaldehyde --- chemo free treatment --- Staphylococcus epidermis --- rheumatoid arthritis --- microbiome --- co-occurrence network --- immune epigenetics --- 2 --- autoimmunity --- superoxide dismutase --- precision medicine --- metabolism --- adoptive cell transfer (ACT) --- gut barrier --- antibiotics --- checkpoint inhibitors --- probiotics --- microbiota --- Candida albicans --- Enterococcus faecalis --- chronic liver diseases --- TCR --- anaerobic bacteria --- HSV2 --- bacteriocins --- methotrexate --- microbial interactions --- T cells --- virus --- mice --- lymphoid malignancies --- HPV --- macrophages --- anti-TNF-? --- inflammation --- chondroitin sulfate disaccharide --- immunotherapy --- genomics --- immuno-oncology --- diet --- aerobic bacteria --- immunological niche --- melanin --- health --- chemokines --- gut microbiota --- cutaneous immunity --- HIV --- TIL --- cancer --- global network

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The first national conference with international participation, “Fundamental aspects of atherosclerosis: scientific research for improving the technologies of personalized medicine”, was held in Novosibirsk on 15 October, 2021. The purpose of this conference was to disseminate the latest basic and clinical findings in the fields of etiology, clinical characteristics, and modern diagnostics and treatments of atherosclerosis among various relevant specialists. The conference was intended for practicing cardiologists, primary care physicians, medical geneticists, and physician–scientists. The conference included plenary sessions, specialty sessions, satellite symposia, an open competition for young scientists.

metalloproteinases --- calcification --- atherosclerosis --- multiplex assay --- coronary heart disease --- aspirin --- resistance --- non-sensitivity --- antiplatelet --- light transmission aggregometry --- Plateletworks® --- familial hypercholesterolemia --- targeted sequencing technologies --- multiplex ligation-dependent probe amplification --- LDLR --- APOB --- ABCG5 --- APOC3 --- LPL --- SREBF1 --- rare variants --- coronary atherosclerosis --- ischemic heart disease --- saturated fatty acids --- monounsaturated fatty acids --- polyunsaturated fatty acids --- oxidative stress --- superoxide dismutase --- catalase --- glutathione peroxidase --- cumulative LDL-C level --- prognosis --- DNA methylation --- epigenetic age --- myocardial infarction --- acute coronary syndrome --- population --- nested case-control --- HAPIEE project --- HAPIEE study --- atrial fibrillation --- arterial hypertension --- obesity --- diabetes mellitus --- aging --- determinants --- prevalence --- Russian population cohort --- Cox regression analysis --- adiponectin --- leptin --- interleukin-6 --- epicardial adipose tissue --- perivascular adipose tissue --- circulating biochemical markers --- coronary atherosclerosis presence and severity --- integrated biomarker (i-BIO) --- validation --- visual markers --- lipoprotein(a) --- immune cells blood count --- n/a